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Inadequate delivery of macromolecules limits the efficacy of
systemic therapies of tumours with cytokines, monoclonal anti-
bodies, and oligonucleotides (Presant et al, 1994; Jain, 1994;
1998). One of the major barriers to the delivery is the tumour
microvessel wall. The permeability of the wall to macromolecules
is heterogeneous in tumours: there exist regions where tumour
vessels are nearly impermeable to these molecules, while other
regions are much more leaky than normal vessels (Yuan et al,
1994). The leakiness of tumour vessels is presumably caused by
the large pores (~ several hundred microns) in the vascular
endothelium (Yuan et al, 1995), and discontinuity in the basement
membrane (Bosman et al, 1985). Therefore, electrically neutral
macromolecules and nanoparticles circulating in the blood
accumulate preferentially in tumour tissues.
In addition to the size selectivity, the transvascular transport is
influenced by the charge of molecules. The charge-dependence of
the transvascular transport is especially important for gene
delivery to tumours, using polycationic liposomes (Gao and
Huang, 1995) or amino polymers (Goldman et al, 1997). These
non-viral vectors have shown promising results in gene delivery
across the cell membrane (Gao and Huang, 1995; Goldman et al,
1997). Recently, Thurston et al (1998) demonstrated that cationic
liposomes are preferentially taken up by angiogenic tumour
endothelium, mostly through vesicular organelles.
In normal tissues, the luminal endothelial membrane is nega-
tively charged (Curry et al, 1987; Turner et al, 1983; Vehaskari
et al, 1984; Deen et al, 1980; Baldwin et al, 1991; Dermietzel et al,
1983). Thus, it restricts the extravasation of anionic macromole-
cules, as has been demonstrated in cultured endothelial cell mono-
layer (Sahagun et al, 1990) and various normal tissues (Jain, 1997;
Curry et al, 1987; Turner et al, 1983; Vehaskari et al, 1984; Deen
et al, 1980; Baldwin et al, 1991; Dermietzel et al, 1983; Adamson
et al, 1988; Barrowcliffe et al, 1990; Gandhi and Bell, 1992;
Gilchrist and Parker, 1985; Haraldsson et al, 1983; Khaw et al,
1991; Leypoldt and Henderson, 1993; Michel and Phillips, 1985;
Öjteg et al, 1987; Parker et al, 1985; Rasio and Goresky, 1985;
Triguero et al, 1989). Adamson et al (1988) have demonstrated
that the microvascular permeability to a-lactalbumin (Mr = 14 176,
net charge –10) is approximately 50% of that to ribonuclease
(Mr = 13 683, net charge +4), suggesting that the microvascular
permeability to the positively charged molecules is higher than the
permeability to the negative ones. The transport restriction of
anionic macromolecules is crucial for maintaining a fluid
homeostasis in the body, due to the osmotic effect (Curry, 1984).
However, tumour vessels are significantly different from normal
vessels. The role of molecular charge in the transport across
tumour vessel wall is still unknown. To address this issue, we
quantified tumour microvascular permeability of bovine serum
albumin (BSA) and IgG, as well as their derivatives, on which
different charge groups were covalently attached. The quantifica-
tion was based on the intravital fluorescence microscopy, in
combination with the human colon adenocarcinoma LS174T
model implanted in the transparent dorsal skinfold chambers in
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DOI: 10.1054/ bjoc.1999.1171, available online at http://www.idealibrary.com on severe combined immunodeficient (SCID) mice. The results of the
present study may have important implications in designing
vehicles for delivering genes and drugs to solid tumours.
MATERIALS AND METHODS
Animals and tumour model
Dorsal skinfold chambers bearing the LS174T tumour were
prepared in male severe combined immunodeficient (SCID) mice
as described earlier (Leunig et al, 1992). In brief, titanium cham-
bers were implanted in the dorsal skin of mice (male, 6–8 weeks
old, 25–35 g) under anaesthesia (75 mg ketamine hydrochloride
and 25 mg xylazine kg–1 body weight, subcutaneously). Two days
later, 2 ml of a dense suspension of human colon carcinoma cells
(approx. 2 ´ 105 cells in phosphate buffered saline) was inoculated
onto the striated muscle layer of the subcutaneous tissue in the
chambers. Experiments for measurement of permeability were
performed 2 weeks after tumour cell implantation.
Preparation of charge-modified BSA
Bovine serum albumin (A7030; Sigma Chemical Co, St. Louis,
MO, USA) was first fluorescently labelled by conjugation
with carboxytetramethylrhodamine succimidyl ester (C-1171;
Molecular Probes, Eugene, OR, USA). Free dye was removed on a
gel filtration column (Econo-Pac 10DG; Bio-Rad Laboratories,
Herculaes, CA, USA) equilibrated with 50 mM phosphate
buffered saline (PBS; Sigma) containing 0.002% sodium azide
(Sigma). This procedure yielded a molar dye/protein ratio of 1.3.
Subsequently, aliquots of the BSA solution were anionized by
succinylation, or cationized by conjugation with hexamethylenedi-
amine. For succinylation (Klotz, 1967; Rennke and Venkatchalam,
1978), 10 mg of succinic anhydride (Sigma) in 50 ml of dimethyl-
sulfoxide (DMSO, Sigma) was added dropwise in small incre-
ments to the solution of 10 mg protein in 1 ml of 0.2 M
bicarbonate buffer, pH 8.0. During the incubation time (30 min at
room temperature) pH was maintained at 8.0–8.5. For cationiza-
tion (Triguero et al, 1989; Kumagai et al, 1987; Hoare and
Koshland, 1967), free carboxylic groups of the protein (10 mg in
1 ml of 5 mM MES, pH 5.3, if necessary pH was maintained at
5.3 with 1 M HCl) were activated with 1-ethyl-3-(3-dimetl-
aminopropyl)carbodiimide (CDI, Sigma). For this purpose, two
portions of CDI (10 mg in 100 ml water) were added to the protein
solution with a 10 min interval. Immediately after the addition of
the second portion of CDI, the activated protein was added upon
stirring into 2 ml of 2 M hexamethylenediamine (Sigma) in water.
pH of the solution was adjusted to 6.8 and the mixture was incu-
bated for 5 h at room temperature. After conjugation, the products
were purified by overnight dialysis, and high molecular weight
aggregates were removed by elution through a Sepharose CL-6B
column (Pharmacia). The major protein peak was pooled and
stored at 4°C.
Preparation of charge modified IgG
The solvent of mouse monoclonal IgG antibody (MOPC21;
M-9269, Sigma) was exchanged to 0.2 M sodium bicarbonate
buffer on a gel filtration column (Econo-Pac 10DG; Bio-Rad) and
the solution concentrated to 1 mg protein ml–1 by centrifugal
filtration (Ultrafree-CL; Millipore, Bedford, MA, USA). pH was
adjusted to 9.3. For fluorescent labelling, Cyanine 3 monofunc-
tional dye (Cy3-Mono-OSu) (PA13104; Amersham Life Science,
Arlington Heights, IL, USA) was used to yield high fluorescence
intensity, which allowed in vivo experiments with small amounts
of IgG (0.5 mg IgG animal–1). Cy3-Mono-OSu was added at a
ratio of 2 mg dye 10 mg protein–1 and the solution stirred at room
temperature for 60 min. Free dye was removed on a gel filtration
column (Econo-Pac 10DG; Bio-Rad) equilibrated with 50 mM
PBS containing 0.002% sodium azide (Sigma), and the solution
concentrated to 1.8 mg protein ml–1 by centrifugal filtration.
Subsequently, anionic and cationic derivatives of IgG were
prepared as described above for BSA.
Measurement of molecular charge and weight
We did not quantify the net charge per molecule, since it depends
on local tissue environment, especially extracellular pH which
is heterogeneous in solid tumours (Helmlinger et al, 1997).
Therefore, only the fraction of free lysine amino-groups in
proteins that were modified with charge-bearing groups was quan-
tified, using trinitrobenzenesulphonic acid titration method
(Fields, 1971). We found that approximately 25–35% of all amino-
groups accessible for modification was modified with charge-
bearing groups. In addition, isoelectric points of the proteins were
determined by isoelectric focusing using polyacrylamide gel slabs
on a vertical electrofocusing apparatus. pI was quantified by
comparison with protein standards (Bio-Rad) after Coomassie
Blue staining of the gels. The proteins’ molecular weight was
analysed by SDS-PAGE (Mini-Protean II; Bio-Rad) with and
without reducing agent b-mercaptoethanol in the sample buffer.
Molecular size of native and charge-modified proteins was esti-
mated by HPLC on analytical gel filtration column (Shodex
Protein KW 804; Waters, Milford, USA) with precolumn (Shodex
Protein WS 800P) using Waters 600E system controller and 996
photodiode array detector. Mobile phase was 0.05 M phosphate
buffer at pH 7.4 and flow rate was 0.7 ml min–1. We used three
standard molecules: chymotrypsin (MW 23 kDa), amylase (MW
200 kDa), and thyroglobulin (MW 669 kDa), and found that posi-
tive, negative and native BSA and IgG gave indistinguishable
peaks. All BSAs showed the same peak not very far from
chymotrypsin, while all IgGs showed the same peaks close to
amylase. These data indicate that charge modification did not
significantly change the size of molecules.
Measurement of tumour microvascular permeability
Effective microvascular permeability of the different proteins was
measured using fluorescence microscopy as reported previously
(Yuan et al, 1993; 1995). In brief, animals were anaesthetized as
described above and immobilized in a polycarbonate tube on the
microscope stage. The fluorescently labelled protein was
dissolved in PBS and injected into the tail vein as a bolus (0.1 ml
25 g body weight–1). Fluorescence intensity of tumour tissue was
monitored by a 20´ objective of a fluorescence microscope
(Axioplan, Zeiss), and quantified over a period of 20 min by a
photomultipier. We have quantified S/V in different tumours of the
same cell line (LS174T) and found that S/V = 239 ± 82 cm2 cm–3
(Yuan et al, 1993). Therefore, we used the mean value of S/V in
the estimation of microvascular permeability. In separate experi-
ments using three animals per protein, the time constant of plasma
clearance (K) was quantified through collecting arterial blood
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proteins, and fitting these data to an exponential function. Tumour
microvascular permeability from experiments with 6–7 individual
tumours for each of the different proteins, was calculated from
these data according to Yuan et al (1993). Results for microvas-
cular permeability are given as range or median ± standard error of
median. Mann-Whitney U test was used to compare the difference
in tumour microvascular permeability between the altered
proteins.
Mathematical modeling of tumour uptake
Electrical charge of molecules affects both transvascular transport
and plasma clearance of drugs. Therefore, the amount of drug
accumulation in solid tumours depends on the balance between
these two processes. In this study, a two-compartmental model was
used to investigate the effect of charge manipulation on the total
accumulation of drugs in tumours. The governin gequation of the
average concentration of drugs in tumours (C) is as follows:
where P is the vascular permeability, S/V is the vascular surface
area per unit tissue volume, t is the time, CP0 is the plasma concen-
tration (CP) immediately after intravenous injection, and K is the
time constant of plasma clearance. We assumed that the initial
concentration in tumours was zero, thus the solution of equation
1 is:
We further assumed that S/V = 239 cm2 cm–3 (Yuan et al, 1993).
The values of K and P used in the simulation were measured
directly in this study (see Table 1).
RESULTS
Fluorescence microscopy revealed that the different proteins
extravasated homogeneously along the vessel walls. Tumour
microvascular permeability (PV) to anionized and cationized BSA
is shown in Figure 1. Permeability values were low for negatively
charged BSA (PV = 1.11 ± 0.44 ´ 10–7 cm s–1; median ± standard
error of median), and almost fourfold higher to positively charged
BSA (PV = 4.25 ± 0.26 ´ 10–7 cm s–1). Characteristics of tracer
molecules are given in Table 1.
The microvascular permeability in tumours of anionized and
cationized IgG was slightly above values measured for corre-
sponding BSA samples (Figure 2, Table 1). Similar to the data for
charge-modified BSA, cationized IgG revealed highest perme-
ability (Pv = 4.65 ± 0.29 ´ 10–7 cm s–1), and permeability of anion-
ized IgG (PV = 1.93 ± 0.41 ´ 10–7 cm s–1) was below the value
measured for the native protein.
The plasma clearance rate revealed a similar behaviour for both
proteins (Table 1). The time constant of the plasma clearance (K)
was highest for the native proteins, slightly lower for the anionized
compounds, and significantly lower for cationized BSA and IgG.
These results are consistent with the data in the literature (Deen  
et al, 1980).
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Table 1 Characteristics of tracer molecules and their microvascular permeability in tumours. Anionized and cationized BSA and IgG
were prepared from the native proteins as described in Materials and methods. *P < 0.01 vs the corresponding anionized compound
(Mann-Whitney U test)
Name Mr pIa Median Ka Median Pv
a
(range) (range) (100s) (range) (10–7 cm s–1)
Native BSAb 66 000 4.5 80.5 1.61
(77–130) (0.65–1.93)
Anionized BSA 64 000 »2.0 40.8 1.11
(37–45) (0.95–2.38)
Cationized BSA 64 000 8.6–9.1 12.7 4.25*
(12–13) (3.57–5.34)
Native IgGb 160 000 6.0 50.0 2.82
(34–82) (1.47–4.07)
Anionized IgG 155 000 3.0–3.9 39.3 1.93
(37–44) (1.11–2.53)
Cationized IgG 155 000 8.6–9.3 11.0 4.65*
(5–15) (4.25–5.27)
apI, isoelectric point; K, time constant of concentration decay in the plasma; Pv, microvascular permeability. bData from Yuan et al (1995).
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Figure 1 Microvascular permeability of tumours to anionized
(n = 6 tumours) and cationized BSA (n = 7 tumours). Bars depict median
values of the groups. *P < 0.01 (Mann-Whitney U test)
–t -
KThe effect of charge on the accumulation of molecules in
tumours was investigated, based on the mathematical simulation
of average concentrations. We found that charge modification of
BSA and IgG decreased the total accumulation of drugs (Figure
3A), through either reduction in microvascular permeability or
increase in the plasma clearance. The total accumulation in
tumours could be increased through cationization of drugs, if the
plasma concentration was maintained at a constant level, i.e. the
time constant of plasma clearance, K ® ∞ (Figure 3B). In this
case, the accumulation was affected only by the microvascular
permeability.
DISCUSSION
Molecular charge-dependence of vascular permeability
In comparison to tumour microvascular permeability of native
BSA and native IgG (Table 1, Yuan et al, 1995), the permeability
values were lower for negatively charged BSA and IgG, and more
than twofold higher for the positively charged proteins. The
charge-dependence in vascular permeability in tumours is consis-
tent with observations in normal tissues (Jain, 1997; Curry et al,
1987; Turner et al, 1983; Vehaskari et al, 1984; Deen et al, 1980;
Baldwin et al, 1991; Dermietzel et al, 1983; Adamson et al, 1988;
Barrowcliffe et al, 1990; Gandhi and Bell, 1992; Gilchrist and
Parker, 1985; Haraldsson et al, 1983; Khaw et al, 1991; Leypoldt
and Henderson, 1993; Michel and Phillips, 1985; Öjteg et al, 1987;
Parker et al, 1985; Rasio and Goresky, 1985; Triguero et al, 1989),
suggesting the luminal surface of tumour vascular endothelium is
negatively charged as well.
The effect of molecular charge on microvascular permeability
has been studied in several organs including the mesentery
(Adamson et al, 1988), the kidney (Rennke and Venkatchalam,
1978), the lung (Gilchrist and Parker, 1985) and the brain
(Kumagai et al, 1987). On the one hand, negatively charged glyco-
proteins, coated on the luminal side of the endothelium known as
glycocalyx in various normal organs (Turner et al, 1983; Vink and
Duling, 1996) form a physiological barrier for the transcapillary
movement of negatively charged molecules. Vehaskari et al (1984)
have demonstrated that intravenous injection of polycations causes
a significant increase in haematocrit and decrease in plasma
albumin in nephrectomized rats. These results suggest that the
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Figure 3 Mathematical simulation of the average concentration (C) of BSA and IgG in a solid tumour as a function of time. (A) Simulation of the relation
between tumour concentration and plasma concentration (C/CPO) for the different proteins based on our experimental results following bolus injection.
(B) Simulation of the relation between tumour concentration and plasma concentration (C/CPO) for the different proteins, if the plasma concentration was
maintained at a constant level: ‘+’ and ‘–’ indicate anionic or cationic modification of molecules
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Figure 2 Tumour microvascular permeability to anionized (n = 6 tumours)
and cationized IgG (n = 6 tumours). Bars depict median values of the groups.
*P < 0.01 (Mann-Whitney U test)neutralization of the negative charge sites on the vessel wall can
abolish the barrier effect of the glycocalyx layer on the transport of
anionic macromolecules. On the other hand, the negatively
charged endothelial surface may facilitate interactions between
cationic molecules and the vascular endothelium. Kumagai et al
(1987) observed a rapid binding and endocytosis of cationized
albumin to isolated brain capillaries, suggesting that the anionic
barrier facilitates the endothelial absorption and endocytosis of
cationic molecules.
Cationic liposomes have been demonstrated to be taken up by
endothelial cells in an organ-specific pattern with highest accumu-
lation in the lung (McLean et al, 1997). However, angiogenic
endothelial cells in tumours and in chronic inflammation revealed
a preferential uptake of cationic liposomes, with a high proportion
being associated with endothelial fenestrae (Thurston et al, 1998).
Endothelial fenestrae are very frequently found on tumour
endothelium (Roberts and Palade, 1997; Hobbs et al, 1998), and
may thus be the site of extravasation of cationic proteins.
The absorption of cationic molecules to the endothelium and
their subsequent internalization may potentially affect the vascular
permeability measurement, since most techniques used are based
on the quantification of the total accumulation of tracers in the
vicinity of vessels. Therefore, the apparent vascular permeability
data of cationic molecules accounts for the combined effect of the
endothelial uptake (bound plus internalized) and the extravasation.
The exact contributions of individual mechanisms to the apparent
vascular permeability cannot be determined separately. However,
we did not observe a significant staining of tumour vessels with
the fluorescent tracers, indicating that the amount of bound
proteins was insignificant compared to the extravasated molecules.
The ratio of the bound versus extravasated macromolecules should
be much lower in tumours than normal tissues, since tumour
vascular endothelium is leaky (Yuan et al, 1993; 1995; Wu et al,
1993; Gerlowski and Jain, 1986; Dvorak et al, 1995) and the base-
ment membrane is incomplete (Hobbs et al, 1998). Therefore, the
effect of the endothelial uptake on the permeability measurement,
if any, may be less important in tumours.
Plasma clearance of charged macromolecules
The mechanism of the plasma clearance of macromolecules is
different from that of small molecules. The cut-off size of renally
filterable proteins and peptides is approximately 6.3 nm
(Mr ~ 60 000) (Behr et al, 1995), which is slightly smaller than the
size of albumin. For dextran, this size is increased to approxi-
mately 8 nm (Deen et al, 1980), presumably due to the difference
in the molecular configuration. Consequently, the excretion of
proteins larger than the renally filterable size may initially require
catabolism in the liver; and smaller metabolites can then be filtered
and excreted through the kidney (Behr et al, 1995). In addition to
liver and kidney, organs such as the lung (McLean et al, 1997) and
the immune system may be involved in the clearance of charge
modified molecules. Bass et al (1990) have shown that cationiza-
tion of albumin alters its molecular conformation. The confor-
mation change may increase the immunogenicity of exogenous
molecules, in part due to an increased uptake by antigen-pre-
senting cells (Apple et al, 1988). The immune response can cause
vascular leakiness and significantly reduce the plasma half-life of
molecules (Yamamoto et al, 1986; Adamski et al, 1987). However,
such a response was unlikely in our experiments, since the perme-
ability was quantified within 1 h after the intravenous injection of
proteins. Taken together, we hypothesize that the charge-
dependence of the plasma clearance soon after the injection
depends on three effects: microvascular permeability in various
normal tissues, catabolism of the macromolecules in the liver, and
the clearance of their metabolites in the plasma through the kidney.
Implications for drug and gene delivery to solid
tumours
In conclusion, positively charged macromolecules extravasate
faster in solid tumours compared to similar sized compounds with
neutral or negative charges, suggesting that cationization may
enhance delivery of therapeutic agents to solid tumours. However,
the rapid clearance of cationic molecules from the plasma
indicates that the charge modification enhances the drug delivery
to normal organs as well. Therefore, caution should be exercised
when such a strategy is used to improve the drug and gene delivery
to solid tumours. This issue is especially important for gene
therapy where polycationic liposomes and amino polymers are
used as the delivering vectors. In general, the tumour specificity
versus the enhanced delivery of drugs and genes has to be
balanced in the development and evaluation of charge-modified
drugs or vectors.
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